State Street Corp Has $3.27 Million Holdings in Sanofi (NASDAQ:SNY)

State Street Corp raised its holdings in Sanofi (NASDAQ:SNY) by 0.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 56,734 shares of the company’s stock after buying an additional 264 shares during the period. State Street Corp’s holdings in Sanofi were worth $3,270,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Stifel Financial Corp grew its stake in shares of Sanofi by 2.0% in the 3rd quarter. Stifel Financial Corp now owns 562,547 shares of the company’s stock worth $32,420,000 after acquiring an additional 10,892 shares in the last quarter. Quantinno Capital Management LP grew its position in Sanofi by 15.8% in the 3rd quarter. Quantinno Capital Management LP now owns 98,876 shares of the company’s stock worth $5,698,000 after purchasing an additional 13,499 shares in the last quarter. Redwood Grove Capital LLC increased its stake in Sanofi by 29.2% in the 3rd quarter. Redwood Grove Capital LLC now owns 356,441 shares of the company’s stock valued at $20,542,000 after buying an additional 80,537 shares during the last quarter. Polar Asset Management Partners Inc. bought a new position in shares of Sanofi during the 3rd quarter worth approximately $3,198,000. Finally, IHT Wealth Management LLC bought a new position in shares of Sanofi in the third quarter valued at approximately $227,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SNY. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

Shares of SNY opened at $48.23 on Tuesday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock’s fifty day moving average price is $49.64 and its two-hundred day moving average price is $52.03. The firm has a market cap of $122.40 billion, a PE ratio of 24.61, a PEG ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.55 EPS. On average, equities research analysts forecast that Sanofi will post 4.06 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.